Pfizer boosts full-year guidance, on track for vaccine deliveries
Pfizer Inc.
$34.31
17:15 22/03/17
Drug giant Pfizer blew past analysts' forecasts for its third quarter, beating on both its top and bottom line and guiding the market consensus higher.
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
The company also said it remained on track to deliver 1.0bn doses of its MRNA vaccine against Covid-19 in both 2021 and 2022 with sales from the shot expected to hit $36bn this year.
For the quarter ending on 30 September, Pfizer posted sales of approximately $24.1bn, which was up from roughly $10.3bn one year before and comfortably ahead of estimates on the Street.
Adjusted earnings per share meanwhile came in at $1.34 (FactSet: $1.08).
Looking ahead, the company guided towards full-year sales of $81.0-82.0bn, against a prior forecast for $78.0-80.0bn, for EPS of $4.13-4.18, which was up from $3.94-4.05.
As of 1259 GMT, shares of Pfizer were trading 3.21% higher to $45.05.